Danuglipron is a small-molecule GLP-1 agonist developed by Pfizer that, in an oral formulation, is under investigation as a therapy for diabetes mellitus. From Wikipedia
The pharmaceutical giant shifts focus to early-stage obesity treatments following the latest setback in its weight-loss drug pipeline.
